Following a full submission:
valganciclovir (Valcyte®): is accepted for restricted use within NHS Scotland.
Indication under review: prevention of cytomegalovirus (CMV) disease in CMV negative patients who have received a solid organ transplant from a CMV positive donor. The marketing authorisation has been amended to allow the duration of CMV prophylaxis in kidney transplant patients to be increased from 100 days to 200 days post-transplantation
SMC restriction: valganciclovir should be initiated by physicians experienced in the care of post-transplant patients. In a randomised controlled study there was a significant reduction in the incidence of CMV disease at 12 months following 200-day versus 100-day prophylaxis.
Download detailed advice207KB (PDF)
- Medicine name:
- valganciclovir (Valcyte)
- SMC ID:
- Prevention of cetomegalovirus (CMV) disease in CMV-negative patients who have received a solid organ transplant from CMV-positive donor
- Pharmaceutical company
- BNF chapter
- Submission type
- Date advice published
- 17 January 2011